From seeking alpha "Today's development suggests that Pfizer is indeed going forward with development of Remoxy". If Pfizer decided to go forward they will do in the best way, they have the management the resources and the experience to be on market very quick. The all development can impact Pain Therapeutics very strong. Share price will surge very fast to the level of $5.00 for sure.
Pfizer has just now (Aug 14) registered specific details of the study at clinicaltrials.gov ~ that means the study has already been designed, requiring significant input - manhours logged by a team of clinical researchers and statistical experimental specialists - of course they're going forward with it! Anybody on this board suggesting they might yet change their mind must think Pfizer is as fickle as a Filipina First Lady.